Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Autologous transplantation and management of younger patients with mantle cell lymphoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Should immunologic strategies be incorporated into frontline ALL therapy?

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  1. Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Mantle cell lymphoma is traditionally conceived as one of the NHL subtypes with the worst prognosis and incurable. In responders to frontline induction with CHOP-like chemotherapy autologous stem cell transplantation (ASCT) is proven superior to interferon maintenance, but does not lead to long-term disease control. The efficacy of CHOP as induction therapy before ASCT in MCL is questioned and there is now evidence that as pretreatment before ASCT, AraC + rituximab leads to deeper remission and prolongs progression-free survival compared to rituximab + CHOP. The treatment goal of complete clinical and molecular remission in younger patients with MCL, is now within reach, based on an integrated approach of intensive AraC containing immunochemotherapy with or without subsequent ASCT, and post-treatment maintenance with rituximab or lenalidomide are now being investigated. Such an integrated approach might lead to a shift of paradigm of MCL from an incurable to a curable lymphoma.
OriginalsprogEngelsk
TidsskriftBest Practice & Research: Clinical Haematology
Vol/bind25
Udgave nummer2
Sider (fra-til)211-20
Antal sider10
ISSN1521-6926
DOI
StatusUdgivet - 2012

ID: 36545725